2026-03-18T10:29:17-07:00 2025-05-31 872635810 Tovella Dowling PC 501 W Broadway Ste 1540 San Diego CA 92101 990 2024-06-01 932180352 Active Site Research Inc ACTI 6174175428 1 Broadway Suite 13-100 Cambridge MA 02142 Joe Torres President 2026-03-18 true true Julie U Nguyen Esq P01881055 6199309332 2024 2025-03-06 01:10:19Z X Joe Torres 2258848 false X activesite.org X 2023 DE To eliminate the risks posed by pandemic threats through the advancement of science and innovation in medical countermeasure development, ensuring the health and well-being of individuals and communities worldwide. 4 3 11 0 630277 2215714 37893 0 224058 5241 854335 2258848 0 0 326274 301142 0 21129 418785 752078 745059 1053220 109276 1205628 126827 1352366 17551 37462 109276 1314904 X To eliminate the risks posed by pandemic threats through the advancement of science and innovation in medical countermeasure development, ensuring the health and well-being of individuals and communities worldwide. true true 330152 The Synthetic Innate Immunity program aims to develop medicines that serve as society's first line of defense against emerging viral outbreaks by taking inspiration from natural mechanisms of innate immunity. By encoding natural or engineered pattern recognition receptors PRRs and interferon-stimulated genes ISGs in DNA delivered to the respiratory tract, the program works to persistently enhance a patient's natural sense-and-respond capacity, potentially providing prophylactic protection against a broad range of respiratory viruses for months. 235675 PAN-2025-001 is a single-site, two-arm, parallel-group superiority randomized controlled trial (RCT) with 1:1 allocation, designed to evaluate whether large language model (LLM) use improves the ability of novice lab participants to independently perform complex biological tasks. Participants attempt a fixed sequence of five laboratory obstacles that represent the core skills required to create a virus via reverse genetics with or without LLM assistance. 222703 37893 The organization periodically provides subject-matter expertise in molecular biology and related life sciences disciplines to AI companies. Such services include responding to technical inquiries and developing advanced scientific problem sets designed to evaluate complex biological reasoning and analytical capabilities in emerging AI technologies. These activities further the organizations scientific research mission and promote the responsible development and evaluation of AI tools. 22057 misc program expenses 22057 810587 true true false false false false false false false false false false false false false true true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 4 0 true 11 true false false false false false false false 0 false false false false false false false X 4 3 false false false false false false false true true false false true true true true true false true true false CA DC MA X X alexander Kleinman 6174175428 1 Broadway Suite 13-100 Cambridge MA 02142 Brian Wang VP thru 3-2025 Vice President 40.00 0.00 X X 74776 0 8719 Alexander Kleinman beg 3-2025 Treasurer 40.00 0.00 X 69802 0 8154 Joe Torres beg 3-2025 President 40.00 0.00 X 75000 0 0 William Bradshaw Secretary 0.50 0.00 X X 0 0 0 Jacob Swett Director 0.50 0.00 X 0 0 0 Ales Flidr Chairman 0.50 0.00 X X 0 0 0 219578 16873 0 false false false 0 2215714 2215714 AI/Biosecurity Services 541900 37893 37893 37893 0 0 0 0 0 0 0 0 Miscellaneous Income 900099 5241 5241 5241 2258848 37893 5241 0 0 0 0 226276 182376 31911 11989 0 52025 42232 7191 2602 0 1190 870 239 81 21651 17651 2916 1084 0 14231 111 14120 25420 25420 0 0 0 42788 35188 7100 500 16003 3435 12516 52 21246 15269 5977 12626 4897 7729 0 158649 61954 94999 1696 6781 1541 2115 3125 0 0 0 0 0 3940 3940 Research & Development 430349 429640 709 Research 11690 11690 Dues & Subscriptions 3665 3000 665 payroll expenses 3018 3018 1672 733 939 1053220 810587 221504 21129 90453 1046342 0 225000 0 0 0 0 0 36374 81024 0 0 0 0 0 0 126827 1352366 17551 37462 17551 37462 X 109276 326194 988710 109276 1314904 126827 1352366 1205628 X false true X true false X 630277 2215714 2845991 0 0 630277 2215714 2845991 1596631 1249360 0 0 224058 5241 229299 3075290 37893 X 0.00000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 2258848 2258848 2258848 1053220 1053220 1053220 Part X : FIN48 Footnote The Organization is a not-for-profit organization that has tax-exempt status under the provisions of the Internal Revenue Code section 501(c)(3). Net income from activities unrelated to the Organization's tax-exempt purpose is subject to taxation. The Organization had no significant unrelated business income during the year ended May 31, 2025, or during the period from inception (June 29, 2023) to May 31, 2024, and accordingly, no provision for income taxes has been made in the accompanying financial statements. The Organization annually files IRS Form 990 - Return of Organization Exempt from Income Tax reporting various information that the IRS uses to monitor the activities of tax-exempt entities. There were no tax penalties or interest recognized during the period or accrued at period end. Form 990, Part III, Line 2 began the PAN-2025-001 and AI/biosecurity programs (see Form 990, Part III, Lines 4b and 4c for program description) Form 990, Part III, Line 3 Discontinued synthetic innate immunity program (see form 990, Part III, Line 4a for program description) Form 990, Part VI, Section B, Line 11b A copy of the Form 990 was provided to the officers and directors for review and comment prior to filing. Form 990, Part VI, Section B, Line 12c Upon engagement, election, or hiring, directors, officers, and key employees agree to comply with the conflict of interest policy and to disclose any conflicts of interest, which are then handled in accordance with the policy. Form 990, Part VI, Section B, Line 15a It is the organization's policy that compensation of any director, officer, or key employee is reasonable. Accordingly, compensation of the executive director was determined based on relevant comparability data followed by written resolution of a disinterested board approving the compensation in compliance with Treas. Reg. 53.4958-6. Form 990, Part VI, Section B, Line 15b See response to Form 990, Part VI, Line 15a. Form 990, Part VI, Section C, Line 18 The organization's Form 1023 and Form 990 returns are accessible to the public through the California Attorney General Charities Registry. The organization can also make such documents available upon written request. Form 990, Part VI, Section C, Line 19 Documents subject to public disclosure or inspection are accessible through the California Attorney General Charities Registry or can be made available upon written request to the organization.